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INTRODUCTION 
 
                     Chronic obstructive pulmonary disease (COPD) is a major cause of 
morbidity and mortality throughout the world. The prevalence and burden of 
COPD are projected to increase in the coming decades due to continued exposure 
to COPD risk factors and the changing age structure of the world’s population. It is 
projected to rank fifth in 2020 in burden of disease caused worldwide, according to 
a study published by the World Bank/World Health Organization1. The disease 
causes a heavy burden on the global health care resources. The costs involved in 
the treatment and evaluation is directly proportional to the pulmonary and the extra 
pulmonary components of the disease2.  
                     ‘Chronic obstructive pulmonary disease (COPD) is defined as a 
preventable and treatable disease with some significant extra pulmonary effects 
that may contribute to the severity in individual patients. Its pulmonary component 
is characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and associated with an abnormal inflammatory 
response of the lung to noxious particles or gases’ 3. 
                     The pathogenesis and clinical manifestations of COPD are not 
restricted to pulmonary inflammation and structural remodeling. Rather, this 
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disorder is associated with clinically significant systemic alterations in 
biochemistry and organ function. The systemic aspects of COPD include oxidative 
stress and altered circulating levels of inflammatory mediators and acute-phase 
proteins. As in other chronic inflammatory conditions, weight loss, muscle 
wasting, hypo proteinemia and tissue depletion are commonly seen in COPD 
patients4. Selective wasting of fat-free mass coupled with impaired respiratory and 
peripheral muscle function and a reduced capacity for exercise occur in COPD 
patients. Indeed, weight loss may directly impact poor prognosis in COPD patients. 
                    The severity of COPD is usually assessed on the basis of a single 
parameter – forced expiratory volume in one second (FEV1).  However the 
patients with COPD have systemic manifestations that are not reflected by the 
FEV1. Hence a multidimensional grading system that assessed the respiratory and 
systemic expressions of COPD was designed to predict outcome in these patients5. 
The four factors that predicted the severity most were the body-mass index (B), the 
degree of airflow obstruction (O) and dyspnea (D), and exercise capacity (E), 
measured by the six-minute–walk test. These variables were used to construct the 
BODE index, a multidimensional 10-point scale in which higher scores indicate a 
higher risk of death.  
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                     The process of allocating scarce medical resources to the most needed 
patients can be extremely difficult in diseases which affect a large number of 
patients. Decision makers need a rational and consistent scoring system that is 
designed to identify those who are maximally in need of a diagnostic or a 
therapeutic intervention under a health-care budget constraint. BODE index has 
been proposed to serve this purpose in patients with chronic obstructive pulmonary 
disease (COPD)6. 
                     In our study we analyzed the BODE index as a predictor of 
hospitalization and severity of systemic involvement. 
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AIMS AND OBJECTIVES  
 
1. To determine whether higher BODE index in chronic obstructive pulmonary 
disease correlates with more years of cigarette smoking. 
2. To determine whether higher BODE index is associated with more days of 
hospitalisation.  
3. To determine whether higher BODE index is associated with more severe 
cardiac involvement. 
4. To determine whether higher BODE index correlates with poor nutritional 
status. 
5. To determine the correlation between BODE index and the level of systemic 
inflammation in patients with COPD.  
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REVIEW OF LITERATURE 
 
                   Chronic obstructive pulmonary disease (COPD) is a lung disease 
characterized by chronic obstruction of lung airflow that interferes with normal 
breathing and is not fully reversible. COPD is one of the leading causes of 
morbidity and mortality worldwide and imparts a substantial economic burden on 
individuals and society. 
DEFINITION 
                Chronic obstructive pulmonary disease (COPD) was initially defined as 
‘a disease state characterized by chronic airflow limitation due to chronic 
bronchitis and emphysema’. Chronic bronchitis has been defined in clinical terms 
as ‘the presence of chronic productive cough for at least 3 consecutive months in 2 
consecutive years. Other causes of chronic productive cough must be ruled out’. 
Emphysema, on the other hand, has been defined by its pathologic description: ‘an 
abnormal enlargement of the air spaces distal to the terminal bronchioles 
accompanied by destruction of their walls and without obvious fibrosis’. 
                     However the definition of COPD has undergone major revision. The 
new GOLD guidelines3 and the ATS/ERS definition7 reflect these scientific 
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advances: “Chronic obstructive pulmonary disease (COPD) is defined as a 
preventable and treatable disease with some significant extra pulmonary effects 
that may contribute to the severity in individual patients. Its pulmonary component 
is characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and associated with an abnormal inflammatory 
response of the lung to noxious particles or gases” 3. While the new guidelines do 
not specifically include chronic bronchitis and emphysema in the definition of 
COPD, it is made clear that they are considered the predominant causes of COPD. 
The airflow limitation is caused by mixture of small airway disease (obstructive 
bronchiolitis) and parenchymal destruction (emphysema) the relative contribution 
of each varies from person to person3. 
EPIDEMIOLOGY 
                     Using the World Health Organization/World Bank Global Burden of 
Disease Study data, the worldwide prevalence of COPD in 1990 was estimated at 
9.34/1000 in men and 7.33/1000 in women8,9. This was an underestimation of true 
prevalence of COPD since the estimates included all age groups. In a large 
epidemiologic study from Korea involving 9,243 subjects, Kim and his colleagues 
reported that the prevalence of COPD was 17.2 % among subjects older than 45 
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years10. There is plenty of information on the prevalence and burden of COPD 
from the developed countries. Such an assessment is rather scarce from most of the 
developing world. 
                    The prevalence of COPD reported in different population based 
studies from India is highly variable11. The prevalence rates in male subjects of 
2.12% to 9.4% in studies reported from the North are generally higher than 1.4% to 
4.08% reported from South India. The respective ranges for female subjects vary 
from 1.33% to 4.9% in the North and from 2.55% to 2.7% in South India. For 
epidemiological assessment, the rounded-off median prevalence rates were 
assessed as 5 percent for male and 2.7 percent for female subjects of over 30 years 
of age11. The disease is distinctly more common in males.  
                  The prevalence was found to increase with increasing age, especially n 
the males, in those with more than 20 pack–yrs of smoking and in low income 
subjects. The male to female ratio had varied from 1.32:1 to 2.6:1 in different 
studies with a median ratio of 1.6:111. 
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RISK FACTORS 
A.  Genetic risk factor:  
a rare recessive severe hereditary deficiency of alpha-1 antitrypsin14, a 
major circulating inhibitor of serine proteases, most commonly seen in 
individuals of Northern European origin15.  
B. Exposure to environmental particles: 
• Tobacco smoke:  
Cigarette smokers have a greater annual rate of decline in FEV1 and a 
greater COPD mortality rate than non smokers16,17. Not all smokers develop 
clinically significant COPD, which suggests that genetic factors must 
modify each individual’s risk18. Passive exposure to cigarette smoke may 
also contribute to respiratory symptoms19 and COPD20 by increasing the 
lungs’ total burden of inhaled particles and gases21,22. 
 
• Occupational dusts organic and inorganic Chemicals: 
 A statement published by the American Thoracic Society concluded 
that occupational exposures account for 10-20% of either symptoms or 
functional impairment consistent with COPD23. 
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• Indoor and Outdoor Air Pollution:  
The evidence that indoor pollution from biomass cooking and heating 
in poorly ventilated dwellings and high levels of urban pollution is an 
important risk factor for COPD continues to grow24-30. This has been proved 
by many case-control studies29.30 and other robustly designed studies . 
 
C. Gender:  
Studies from developed countries31 show that the prevalence of the 
disease is now almost equal in men and women. Some studies have 
suggested that women are more susceptible to the effects of tobacco smoke 
than men32-34.  
D. Infection:  
A history of severe childhood respiratory infection has been 
associated with COPD35-37.  
E. Low birth weight: 
F. Socioeconomic Status:  
The risk of developing COPD is inversely related to socioeconomic 
status 38-40. 
16 
 
G. Poor nutritional status 
H. Co morbidities 
SYMPTOMS 
                     Key symptoms include: Patient is usually a Long-time heavy smoker 
who presents with anyone of the following 
• Long-term (chronic) cough. 
• Chronic mucus (sputum) production  
• Morning "smoker's cough" 
•  At least one episode of "bronchitis" every winter 
• Repeated episodes of acute bronchitis 
• Wheezing and Shortness of breath that is persistent and gets worse, occurs 
during exercise, and gets worse during respiratory infections 
• Shallow cough with the feeling that something is stuck inside the chest 
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                     Patients may have a rapid, sometimes sudden, and prolonged increase 
in symptoms (cough, amount of mucus, and/or shortness of breath), especially if 
the COPD is mainly chronic bronchitis. This is called a COPD exacerbation.  
PATHOPHYSIOLOGY OF COPD 
                   Quantitative evidence of increased expiratory flow resistance in 
emphysema was first obtained in one patient by Neergard and Wirz in 192741. In 
1934, Christie described elastic properties or distensibility of the lung in 
emphysema42. The “golden age” of pulmonary macrophysiology, extending from 
about the 1960s to the 1980s provided new insights regarding the determinants of 
flow limitation at the levels of the airway and parenchyma. Corbin and coworkers 
showed that smoking was associated with the loss of lung recoil pressure and with 
increased static lung volumes (RV, FRC, and TLC), even among individuals who 
had relatively normal FEV143. Up to a point, these changes appeared reversible 
with smoking cessation.  
                    COPD, or chronic obstructive pulmonary disease, is a progressive 
inflammatory disease connecting the airways, lung parenchyma, and vasculature. It 
causes the damage and remodeling of the airways and lung tissue. The 
inflammatory process is a driving aspect in the pathophysiology of COPD. Recent 
verification suggests that the inflammatory response results in a number of effects, 
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including an arrival of inflammatory cells such as macrophages, neutrophils and 
lymphocytes. Thickened airways and structural changes such as increased smooth 
muscle and fibrosis may also be manifested.  
                  Cigarette smoking causes an inflammatory response in the lungs. This 
response does not cease with the removal of the stimulus, but progresses for an 
unlimited period of time. These processes result in emphysema, chronic bronchitis, 
or both. Emphysema begins with a small airway disease and progresses to alveolar 
destruction, with a predominance of small airway narrowing and mucous gland 
hyperplasia. 
       The basic pathophysiologic process in COPD consists of increased 
resistance to airflow, loss of elastic recoil and decreased expiratory flow rate. The 
alveolar walls frequently break because of the increased resistance of air flows. 
The hyper inflated lungs flatten the curvature of the diaphragm and enlarge the rib 
cage. The altered configuration of the chest cavity places the respiratory muscles, 
including the diaphragm, at a mechanical disadvantage and impairs their force-
generating capacity. Consequently, the metabolic work of breathing increases and 
the sensation of dyspnea heightens. 
         Hogg has focused on the importance of small airway obstruction, most 
recently showing that airway remodeling and wall thickening, presence of 
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inflammatory mucous exudates, and B cell and CD8 T cell inflammation are all 
associated with severity of COPD and progression of the disease44. Christie, 
Thurlbeck, and others have championed emphysema as the dominant pathology 
accounting for abnormal physiology, and have shown, for example, that in a 
subgroup of patients, the relationship between flow and recoil pressure is indeed 
normal. While many important insights came from this line of investigation, to this 
day we still do not understand the relative contribution of small airway obstruction 
versus emphysema in an individual patient, nor the potential relationship between 
these two lesions. This line of investigation is still fruitful, particularly with the 
ongoing revolution in imaging. 
THE ELASTASE:ANTIELASTASE HYPOTHESIS 
                        Just over 40 years ago, two lines of evidence, one experimental and 
one clinical, suggested that emphysema is caused by destruction of elastic fibers by 
elastases. The first was by Laurell and Eriksson who, in 1963, described five 
patients with deficiency of α-1AT, the primary inhibitor of the neutral serine 
proteinase neutrophil elastase (NE). Three of these five patients had emphysema45. 
The second came in 1965 when Gross and coworkers instilled papain into the lungs 
of rodents in an attempt to produce granulomas. Instead they found emphysema46.  
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                     Subsequently, investigators have instilled a variety of proteinases into 
animal lungs. Kuhn and colleagues47, Senior and coworkers48, Janoff and 
associates49, and Snider and colleagues50 were among the group of investigators 
who subsequently demonstrated that only elastolytic proteinases—including 
pancreatic elastase and the more relevant human neutrophil elastase (HNE)—
caused emphysema. Hoidal’s group showed that proteinase 351 also caused 
destructive lung disease. These seminal experiments formed the basis for the 
elastase : antielastase hypothesis, which states that the relative balance between 
elastases and their inhibitors determines the susceptibility of the lung to the 
destruction characteristic of emphysema. 
INFLAMMATION–EXTRACELLULAR MATRIX TURNOVER 
         A classic study by Damiano and coworkers correlated the presence of 
HNE with COPD using immunogold staining52. However, other studies actually 
showed a negative correlation between emphysema and HNE or neutrophil 
number53, 54. As discussed above, macrophages are abundant in COPD, yet the 
capacity of the macrophage to degrade elastin and hence contribute to disease 
pathogenesis was unproven until Senior and colleagues demonstrated that 
macrophages produce elastolytic matrix metalloproteinases55,56, and Chapman and 
coworkers found elastolytic cysteine proteinases57.  
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          Retamales and colleagues58 found that even in end-stage lung disease, 
long after smoking cessation, there remains an exuberant inflammatory response. 
This suggests that the mechanisms of cigarette smoke–induced inflammation that 
initiate the disease differ from mechanisms that sustain inflammation after 
smoking cessation. Moreover, this study suggests that multiple inflammatory (and 
likely structural) cells interact to cause COPD, and that focusing on single cells 
and proteinases in isolation will not provide a comprehensive understanding of the 
disease process.  
          Cigarette smoke causes constitutive macrophages to produce MMP-
12, which, in turn, cleaves elastin into fragments chemotactic for monocytes. This 
positive feedback loop perpetuates macrophage accumulation and lung destruction. 
The concept that proteolytically generated elastin fragments mediate monocyte 
chemotaxis was proven by Senior and coworkers59 and Hunninghake and 
colleagues60.At the very least, this study demonstrates a critical role for 
macrophages in the development of emphysema and unmasks a proteinase-
dependent mechanism of inflammatory cell recruitment. Of note, last year 
Grumelli and coworkers found that human CD8+ T cells derived from patients 
with COPD generate interferon (IFN)-γ–inducible chemokines that also function to 
upregulate expression of human macrophage MMP-1261. Studies by Churg and 
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coworkers demonstrate that acute neutrophil inflammation secondary to smoking is 
related to MMP-12–dependent tumor necrosis factor (TNF) shedding 62. 
OXIDANT–ANTIOXIDANT BALANCE 
            Cigarette smoke and inflammatory cells have the capacity to produce 
reactive oxygen species, and they have been postulated to play a variety of roles in 
the pathogenesis of emphysema. One intriguing finding was that cigarette smoke 
can oxidize a methionine residue in the reactive center of A1PI, inactivating A1PI 
and thus altering the elastase:antielastase balance. Oxidants cannot degrade 
extracellular matrix but might modify elastin, making it more susceptible to 
proteolytic cleavage.  
            Recently, Barnes and colleagues have found that cigarette smoke 
oxidizes and inactivates histone deacetylase 2 (HDAC2), which acts to counter 
histone acetylase (HAT)63. Acetylation of histone unwinds chromatin, allowing 
transcriptional complexes to bind to DNA. Thus, in the absence of HDAC2, RNA 
polymerase II and NF-kβ form a proinflammatory transcription complex. Finally, 
reactive oxygen species may also promote apoptosis of structural cells, a recent 
concept for initiation of emphysema.  
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APOPTOSIS 
            Kasahara and colleagues found that exposure to agents that initiate 
endothelial cell death (via VEGFRII inhibition) leads to non inflammatory airspace 
enlargement64. Nagai and coworkers then found that epithelial cell death (via 
caspase 3 delivery) also causes emphysema65. As mentioned above, the loss of an 
acinar unit results from the destruction of both the extracellular matrix (ECM) and 
the structural cells. These models suggest that death of structural cells may be an 
initiating event, with subsequent release of matrix-degrading proteinases. Whether 
this occurs in human COPD as a primary event is uncertain,  
INEFFECTIVE REPAIR 
                     The ability of the adult lung to repair damaged alveoli appears 
limited. In fact, as we define genetic predisposition to COPD, we speculate that 
smoking routinely leads to inflammation and lung damage, and those at risk lack 
the capacity to repair this damage. In emphysema, aberrant alveolar and 
extracellular matrix repair results in coalesced and enlarged airspaces with 
depleted and disordered parenchymal elastic fibers, and excess and abnormally 
arranged collagen.  
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SYSTEMIC INVOLVEMENT IN COPD 
          The pathogenesis and clinical manifestations of COPD are not 
restricted to pulmonary inflammation and structural remodeling. Rather, this 
disorder is associated with clinically significant systemic alterations in 
biochemistry and organ function. The systemic aspects of COPD include oxidative 
stress and altered circulating levels of inflammatory mediators and acute-phase 
proteins. Indeed, an impaired endogenous oxidant-antioxidant balance66-68 has been 
reported in patients experiencing exacerbations of COPD, and others have observed 
altered circulating levels of several cytokines and adhesion molecules in patients 
with stable disease. As in other chronic inflammatory conditions, weight loss, 
muscle wasting, and tissue depletion are commonly seen in COPD patients. 
        Wasting is a generally occurring manifestation in a wide variety of 
different chronic conditions and can be considered to be an important systemic 
manifestation as a loss of > 40% of actively metabolizing tissue is incompatible 
with life69-70. The body cell mass (BCM) represents the actively metabolizing 
(organs) and contracting (muscles) tissue. This BCM cannot be measured directly. 
Changes in BCM can be clinically recognized by decrease in body mass index 
(BMI) in general and by loss in fat-free mass (FFM) in particular. In a 
retrospective study of 400 patients with COPD, Schols et al71 demonstrated that 
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low body mass index (BMI), age, and low PaO2 were significant independent 
predictors of increased mortality rates. After stratification of the group into BMI 
quintiles, a threshold value of 21 kg/m2 was identified below which the mortality 
risk was clearly increased. 
 
SPIROMETRIC CLASSIFICATION OF COPD SEVERITY 
                     The present widely accepted classification of COPD is mainly based 
on the FEV1 values1. It is as follows 
Stage I: Mild COPD –  
Characterized by mild airflow limitation (FEV1/FVC < 0.70; FEV1 >/= 80% 
predicted). Symptoms of chronic cough and sputum production may be present. 
Patients are usually unaware of the illness.  
Stage II: Moderate COPD –  
Characterized by worsening airflow limitation (FEV1/FVC < 0.70; 50% </= 
FEV1 < 80% predicted), with shortness of breath typically developing on exertion 
with or without cough and sputum production. This is the stage at which patients 
typically seek medical attention. 
26 
 
Stage III: Severe COPD –  
Characterized by further worsening of airflow limitation (FEV1/FVC < 0.70; 
30% </= FEV1 < 50% predicted), greater shortness of breath, reduced exercise 
capacity, fatigue, and repeated exacerbations that almost always have an impact on 
patients’ quality of life.  
Stage IV: Very Severe COPD –  
Characterized by severe airflow limitation (FEV1/FVC < 0.70; FEV1 < 30% 
predicted or FEV1 < 50% predicted plus the presence of chronic respiratory 
failure). Respiratory failure is defined as arterial partial pressure of oxygen (PaO2) 
less than 8.0 kPa (60 mm Hg) with or without arterial partial pressure of CO2 
(PaCO2) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level.  
LIMITATIONS OF SPIROMETRIC CLASSIFICATION 
         The spirometric classification, though good in many ways is not full 
proof for the assessment of severity of COPD. The FEV1 is essential for the 
diagnosis and quantification of the respiratory impairment resulting from COPD72-
74. In addition, the rate of decline in FEV1 is a good marker of disease progression 
and mortality75,76. However, the FEV1 does not adequately reflect all the systemic 
manifestations of the disease. For example, the FEV1 correlates weakly with the 
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degree of dyspnea77, and the change in FEV1 does not reflect the rate of decline in 
patients' health78. More important, prospective observational studies of patients 
with COPD have found that the degree of dyspnea79 and health-status scores80 are 
more accurate predictors of the risk of death than is the FEV1. Thus, although the 
FEV1 is important  to obtain and essential in the staging of disease in any patient 
with COPD, it alone as the sole parameter of severity does not throw light on the 
systemic involvement and progession of the disease.  
 
BODE INDEX 
           Due to reasons above stated, researchers described a new index – 
BODE index, for the comprehensive evaluation of patients with COPD. This 
multisystem grading index has four variables. 
• Body mass index 
• Obstruction to airflow (FEV1) 
• Dyspnea (MMRC dyspnea scale) 
• Effort tolerance (6 minute walk test) 
28 
 
           Each variable in the index correlates independently with the prognosis 
of COPD, is easily measurable, and  serves as a surrogate for other potentially 
important variables. In the BODE index, two descriptors of systemic involvement 
were included: the body-mass index and the distance walked in six minutes. Both 
are simply obtained and independently predict the risk of death81-83. It is likely that 
they share some common underlying physiological determinants, but the distance 
walked in six minutes contains a degree of sensitivity not provided by the body-
mass index. The six-minute walk test is simple to perform and has been 
standardized84. Its use as a clinical tool has gained acceptance, since it is a good 
predictor of the risk of death among patients with other chronic diseases, including 
congestive heart failure84 and pulmonary hypertension. Indeed, the distance walked 
in six minutes has been accepted as a good outcome measure after interventions 
such as pulmonary rehabilitation.  
          The body-mass index was also an independent predictor of the risk of 
death and was therefore included in the BODE index. We evaluated the 
independent prognostic power of body-mass index in our cohort using different 
thresholds and found that values below 21 were associated with an increased risk of 
death, an observation similar to that reported by Landbo and coworkers in a large 
population study79.  
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          The Global Initiative for Chronic Obstructive Lung Disease and the 
American Thoracic Society recommend that a patient's perception of dyspnea be 
included in any new staging system for COPD. Dyspnea represents the most 
disabling symptom of COPD; the degree of dyspnea provides information 
regarding the patient's perception of illness and can be measured. The MMRC 
dyspnea scale is simple to administer and correlates with other dyspnea scales and 
with scores of health status80. Furthermore, in a large cohort of prospectively 
followed patients with COPD, which used the threshold values included in the 
BODE index, the score on the MMRC dyspnea scale was a better predictor of the 
risk of death than was the FEV1.  
                        The BODE index combines the four variables by means of a simple 
scale. Weighting the variables included in the index did not improve the predictive 
power of the BODE index. Most likely, it failed to do so, because each variable 
included has already proved to be a good predictor of the outcome of COPD. 
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MATERIALS AND METHODS 
SETTING 
Institute of internal medicine 
Madras Medical college and Government General hospital 
Chennai – 600 003 
INSTITUTIONAL ETHICS COMMITTEE APPROVAL  
Obtained  
STUDY DESIGN 
                    To evaluate the BODE index as a predictor of hospitalization and 
severity of systemic involvement in patients with Chronic Obstructive Pulmonary 
Disease, a cross sectional study design was chosen. 
PERIOD OF STUDY 
May 2007 to July 2008 
SAMPLE SIZE 
Cases : 90 ; controls : 30 
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INCLUSION CRITERIA 
• Male patients with symptoms suggestive of COPD as cases 
• Male patients who came for master health check up as controls  
EXCLUSION CRITERIA 
• Spirometry proved bronchial asthma defined as an increase in the FEV1 of 
more than 15 percent above the base-line value or of 200 ml after the 
administration of a bronchodilator 
• recent myocardial infarction < 4months 
• unstable angina  
• congestive heart failure (NYHA class III or IV) 
• inability to perform spirometry or 6 minute walk test  
• Unrelated life threatening major illness  
• liver disease 
• patients with acute exacerbation 
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STUDY PROTOCOL 
           A total of 120 patients who attended our outpatient clinic at the 
Madras Medical College and Government General Hospital, Chennai were 
enrolled into the study. Of these, 90 patients with symptoms suggestive of COPD 
were selected as cases and 30 patients who came for Master health checkup were 
selected as controls. 
                The patients with the following diagnostic criteria (according to the 
GOLD guidelines) were defined as having COPD 
1. the presence of cough and sputum production for at least 3 months in each of 
the two consecutive years 
2. exertional dyspnoea 
3. physical examination showing 
 (a) Signs of airflow limitation like prolonged expiration and expiratory 
wheeze which is not fully reversible;  
(b) Signs of hyperinflation 
4. Spirometry showing post bronchodilator FEV1/FVC ratio < 0.70 
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                    The present analysis was restricted to male patients only, who met the 
acceptability and reliability criteria of the American Thoracic Society to improve 
the diagnostic accuracy as sex may be a confounding factor in many of the 
parameters assessed. 
                     For each enrolled subject, detailed history of smoking, personal and 
family medical histories were obtained. On the day of enrollment, height and 
weight were measured twice during the examination. Weight was measured to the 
nearest 100 grams with bare foot. Height was measured to the nearest mm with the 
stadometer. Body mass index (BMI) was calculated by the formula. 
BMI = Weight in Kgs / (Height in Ms)2 
          Spirometry was performed with an equipment that met the American 
thoracic society performance criteria, in each of the cases on enrollment into the 
study and 20 minutes following the administration of salbutamol nebulisation. To 
adjust for the height, sex, age and sex published prediction equations for forced 
expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were used. 
FEV1 and FVC were calculated. The procedure was repeated on 2 occasions and 
the average value was taken. 
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          A detailed history of the dyspnea experienced by the patient was 
taken. MMRC dyspnea scale was used to score the patients dyspnea. Six minute 
walk test was performed twice with a gap of  30 minutes rest in between and the 
average was taken. Patients were asked to walk on a level ground for maximum 
possible distance within a duration of 6 minutes. Periods of rest taken, was also 
included in the 6 minutes test period. 
          The BODE index was calculated for each patient using the body mass 
index, the threshold value of FEV1, the distance walked in 6 min, and the score on 
the modified Medical Research Council (MMRC) dyspnea scale. The patients 
received points ranging from 0 (lowest value) to 3 (maximal value). For body mass 
index the values were 0 (>21) or 1 (<21). The scores for FEV1 were 0 (more than 
or equal to 65%), 1 (50 – 64%), 2 (36 – 49%) and 3 (less than or equal to 35%). 
The 6 minute walk test scores were 0 (> 350 ms), 1 (250 – 350 ms), 2 (150 – 249 
ms) and 3 (< 150 ms). The MMRC dyspnea class 0 and I were given 0 points, class 
II – 1 point, class III – 2 points and class IV – 3 points. The points for each 
variable were added, so that the BODE index ranged from 0 to 10 points in each 
patient. The BODE score of 0 – 2 was taken as mild COPD. Scores between 3 – 5 
was considered as moderate disease and those more than or equal to 6 was 
considered as severe COPD. 
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MMRC dyspnea scale   
 
Grade 0 – no dyspnea / only on severe exertion 
Grade 1 – dyspnea on hurrying / walking up a hill 
Grade 2 – walks slower than normal at level/ pause while walking on level ground 
Grade 3 – stops for breath after walking 100 yards/few mins on level ground 
Grade 4 – too breathless to leave the house/ dyspnea on dressing 
 
BODE INDEX: 
 
BODE score 0  1 2 3 
FEV1 >/= 65 %  50 – 64% 36 – 49% < /= 35% 
6 min walk 
test 
>350 ms   250 – 349ms 150 – 249 ms <149 ms 
Dyspnea 
scale 
0 – 1  2 3 4 
BMI > 21 kg/m2 <21 kg/m2   
 
Mild COPD Æ 0 – 2  
Moderate COPD Æ 3 – 5 
Severe COPD Æ >/= 6 
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                      A detailed history regarding number of days of hospital admission in 
the last two years was obtained from the patients response to the question  “how 
many days have you been admitted in hospital in the past 2 years due to reasons 
related to COPD ?” Patient’s discharge cards were also reviewed.  
                    A standard 12 lead ECG was taken for each of the individual patients. 
QRS axis was determined by plotting the QRS potentials on a graph with lead I as 
X axis and aVF as Y axis. – 30 to + 90 was considered as normal axis, – 30º to – 
90º as left axis , +90º to +180º as right axis and – 90º to + 180º was considered as 
north west axis. Echo cardiography was performed using 2D echo in the institute 
of cardiology, Madras Medical College. Ejection fraction and pulmonary pressure 
gradient was assessed. Pulmonary artery hypertension was graded as mild, 
moderate and severe.  
           Hemoglobin estimation was performed according to the routine 
standards using an automated analyzer at the biochemistry lab attached to the 
institute of biochemistry, Madras Medical College and Government General 
Hospital. CRP was estimated in the lab using the latex agglutination method. 
Agglutination at a dilution of 6 or less was considered as negative result. Positive 
result was expressed as the dilution at which agglutination occurred.  
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STATISTICAL ANALYSIS 
 
                   Statistical analysis was carried out in all the 120 subjects (including 90 
COPD patients and 30 controls) after categorizing the variable. Baseline data was 
collected from patients without and with mild, moderate and severe COPD. Ages, 
body mass index, days of hospitalization, mean hemoglobin concentration, QRS 
axis, ejection fraction, pulmonary hypertension, serum albumin concentration, and 
CRP of all subjects were the parameters analyzed.  
                   The significance of difference in means between two groups was 
analyzed using the one way ANOVA F-test and the significance of difference in 
proportions by the Chi square test. Multiple comparisons were done by fishers least 
significant difference (LSD) t-test. Statistical significance was taken when the p 
value was less than 0.05.  
                   Statistical analysis was carried out using the standard formula. 
Microsoft excel 2007 and SPSS (statistical package for social sciences)version 13 
software was used for data entry and analysis. 
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RESULTS AND OBSERVATIONS 
 
                   A total of 120 patients including 90 patients with COPD as cases and 
30 healthy individuals as controls were enrolled in the study. All the cases and 
controls were males. Among patients with COPD, there were 32 (35.56%) patients 
who had mild COPD with a BODE score between 0 – 2. Moderate (BODE score of 
3 – 5) and severe COPD (BODE score more than or equal to 6) groups had 29 
patients (32.22%) each. 
Table 1: Age wise distribution in years 
Group N Mean 
(yrs) 
Std. deviation One way 
ANOVA  F-
test 
Control 30 54.70 5.603 
Mild (0-2) 32 53.47 7.362 
Moderate (3-5) 29 55.00 8.627 
Severe (>/=6) 29 59.93 7.606 
Total 120 55.71 7.679 
 
F=4.440 
P=0.005 
significant 
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                    The average age of participants in the study was 55.71 years. Among 
the COPD patients, BODE index was found to increase with age with the mild 
group having a mean age of 53.47 years, moderate group 55.00 years and the 
severe group with 59.93 years as the mean age. The difference was statistically 
significant with a P value of 0.005. 
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Table 2: Smoking status 
 
Smoker 
Yes No 
 
Groups 
N % N % 
 
Total N 
Pearson 
chi square 
test 
Control 12 40.0 18 60 30 
Mild 14 43.7 18 56.3 32 
Moderate 19 65.5 10 34.5 29 
Severe 26 89.7 3 10.3 29 
Total 71 59.2 49 40.8 120 
 
X2 -19.352 
P =0.000 
significant 
 
 
 
                    The proportion of smokers was higher in the higher BODE index 
group compared to the lower index group. There was no significant difference 
between the control group and the lower score group. Thus smoking status had a 
positive risk correlation with higher BODE index (P = 0.000).  
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Table 3: Smoking in pack years 
 
Group N Mean 
(pack yrs) 
Std. deviation Oneway 
ANOVA F test
Control 30 4.55 5.603 
Mild 32 7.42 7.362 
Moderate 29 15.07 8.627 
Severe 29 26.90 7.606 
Total 120 13.26 7.679 
 
F = 26.936 
P = 0.000 
Significant 
 
                  The study revealed that the BODE score was significantly associated 
with the number of pack years of smoking. It was 4.55 pack yrs in controls, 7.42 
pack yrs in mild cases, 15.07 in moderate and 26.90 in severe cases. On multiple 
comparison by LSD the difference between control group and mild group was not 
statistically significant but that of the other 2 groups were highly significant (P = 
0.000). 
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Table 4: Body Mass index 
 
Group N Mean 
(kg/m2) 
Std. 
deviation 
Oneway 
ANOVA F 
test 
Multiple 
comparison 
(LSD) 
Control 30 24.294 2.544 
Mild 32 22.476 2.455 
Moderate 29 21.711 2.552 
Severe 29 20.260 3.212 
Total 120 22.210 3.035 
 
F = 11.431 
P = 0.000 
Significant 
1Vs2,3,4 
2Vs1,4 
3Vs1,4 
4Vs1,2,3 
P = 0.05 
 
 
                   The average BMI of the patients in our study was 22.21 kg/m2. The 
control group had a BMI of 24.294 kg/m2 with a standard deviation of 2.544. The 
BMI was found to be significantly lower in patients with COPD. It was 22.476 
kg/m2 (standard deviation –2.455) in the mild group, 21.711 (std. deviation – 
2.552) in the moderate group and 20.260 (std. deviation – 3.212) in the severe 
group. On multiple comparisons the significance between mild and moderate 
groups was not found to be significant. All other comparisons showed significant 
difference. 
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Table 5: Duration of hospital stay over last 2 years (days) 
Group N Mean 
(days) 
Std. 
deviation 
Oneway 
ANOVA F 
test 
Multiple 
comparison 
(LSD) 
Control 30 0.07 0.365 
Mild 32 0.13 0.492 
Moderate 29 3.17 2.929 
Severe 29 16.00 9.177 
Total 120 4.68 8.041 
 
F = 75.340 
P = 0.000 
Significant 
1Vs3,4 
2Vs3,4 
3Vs1,2,4 
4Vs1,2,3 
P = 0.05 
  
 
                    The study results showed that a higher BODE score was associated 
with a higher incidence of hospital stay due to reasons related to COPD, over the 
past 2 years. The control group and the mild COPD group did not have any 
significant hospital admission during the past 2 years. The average duration of stay 
in the moderate study group was 3.17 days while it was 16 days in the group with 
severe COPD according to the BODE score. Both these values were found to be 
significant on multiple comparisons to other groups. 
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Table 6: Hemoglobin concentration in gm/ dL 
 
Group N Mean 
(gm/dL) 
Std. 
deviation 
Oneway 
ANOVA F 
test 
Multiple 
comparison 
(LSD) 
Control 30 11.040 1.305 
Mild 32 10.713 1.439 
Moderate 29 12.176 1.566 
Severe 29 14.869 1.460 
Total 120 12.153 2.168 
 
F = 50.733 
P = 0.000 
Significant 
1Vs3,4 
2Vs3,4 
3Vs1,2,4 
4Vs1,2,3 
P = 0.05 
 
 
                     Comparing the hemoglobin values in various groups of the study it 
was found that the mean hemoglobin concentration was lower (10.713 gm/dL) in 
those patients with COPD compared to controls (11.04 gm/dL). However this 
correlation was not found to be significant on multiple comparisons trial. The 
values in the other 2 groups were significantly higher (moderate – 12.176 gm/dL 
and severe 14.869 gm/dL). This was found to be statistically significant at a P 
value of 0.05. 
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Table 7: QRS axis in ECG and BODE score 
ECG axis 
Normal RAD LAD North West 
axis 
 
Group 
N % N % N % N % 
Pearson 
chi square 
test 
Control 26 86.7% 0 0     % 4 13.3% 0 0     % 
Mild 27 84.4% 0 0     % 5 15.6% 0 0     % 
Moderate 20 69.0% 9 31.0% 0 0     % 0 0     % 
Severe 1 3.4  % 25 86.2% 0 0     % 3 10.3% 
Total 74 61.7% 34 28.3% 9 7.5  % 3 2.5  % 
 
df= 9.0 
P = 0.000 
significant
 
 
                    The QRS axis was found to vary among the different groups studied. 
The control group had 26 patients with normal axis and 4 with left axis. Mild 
COPD group had 27 patients with normal axis and 5 patients with right axis 
deviation. Out of 29 patients in moderately severe COPD group 20 had normal axis 
and 9 had right axis deviation. In patients with the highest BODE score 1 patient 
had normal axis, 34 had right axis deviation, 9 with left axis deviation and 3 had 
North West axis. 
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Table 8: Ejection fraction Vs BODE score 
Group N Mean 
(%) 
Std. 
deviation 
Oneway 
ANOVA F 
test 
Multiple 
comparison 
(LSD) 
Control 30 73.43 8.597 
Mild 32 65.06 3.089 
Moderate 29 56.45 6.500 
Severe 29 47.31 7.177 
Total 120 60.78 11.689 
 
F = 85.476 
P = 0.000 
Significant 
1Vs2,3,4 
2Vs1,3,4 
3Vs1,2,4 
4Vs1,2,3 
P = 0.000 
 
 
 
                    The Ejection fraction varied considerably among various groups in the 
study. For the control group, mean EF was 73.43% (std. deviation 8.597). The 
mean ejection fraction for the other groups were mild COPD group 65.06% (std. 
deviation 3.089), the moderate COPD group 56.45% (std. deviation 6.500) and the 
severe group 47.31% (std. deviation 7.177). The difference of mean ejection 
fractions was significant between the various groups was statistically significant 
with a P value of 0.000. 
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Table 9: Pulmonary hypertension and BODE score 
 
pulmonary hypertension 
Normal mild moderate severe 
 
Group 
N % N % N % N % 
Pearson 
chi square 
test 
Control 30 100% 0 0     % 0 0     % 0 0     % 
Mild 32 100% 0 0     % 0 0     % 0 0     % 
Moderate 19 65.5% 8 27.6% 2 6.9  % 0 0     % 
Severe 0 0     % 5 17.3% 17 58.6% 7 24.1% 
Total 81 67.5% 13 10.8% 19 15.8% 7 5.8  % 
 
df= 9.0 
P = 0.000 
significant
 
 
                  This study showed that there was no incidence of pulmonary 
hypertension in the controls and the group with mild COPD according to BODE 
scores. In the moderate COPD group 19 patients did not have pulmonary 
hypertension while 8 showed mild and 2 patients had severe PHT. However in the 
severe COPD group all patients had PHT with 13 patients having mild PHT, 19 
having moderate and 7 patients having severe PHT. 
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Table 10: Albumin concentration Vs BODE score 
 
Group N Mean 
(gm/dL) 
Std. 
deviation 
Oneway 
ANOVA F test 
Multiple 
comparison 
(LSD) 
Control 30 3.900 .2901 
Mild 32 3.850 .2664 
Moderate 29 3.462 .4057 
Severe 29 2.997 .4579 
Total 120 3.563 .5084 
 
F = 40.010 
P = 0.000 
Significant 
1Vs3,4 
2Vs3,4 
3Vs1,2,4 
4Vs1,2,3 
P = 0.05 
  
 
                    Albumin concentration was found to progressively decrease with 
increase in BODE score. The mean albumin concentrations were 3.900 gm/dL (std. 
deviation .2901), in the control group, 3.850 gm/dL (std. deviation .4507) in the 
mild group, 3.462 gm/dL (std. deviation 0.4057) in the moderate group and 3.563 
gm/dL (std. deviation 0.5084) in the severe COPD group. The difference was not 
significant between the controls and patients with mild COPD. However the 
difference of the moderate and severe COPD groups with the other groups were 
highly significant (P = 0.000). 
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Table 11: C reactive protein Vs BODE score 
 
Group N Mean Std. 
deviation 
Oneway 
ANOVA F test 
Multiple 
comparison 
(LSD) 
Control 30 2.60 3.410 
Mild 32 7.31 4.993 
Moderate 29 33.72 18.452 
Severe 29 105.93 53.480 
Total 120 36.35 49.577 
 
F = 85.476 
P = 0.000 
Significant 
1Vs3,4 
2Vs3,4 
3Vs1,2,4 
4Vs1,2,3 
P = 0.05 
 
 
                   The marker of systemic inflammation the C reactive protein was found 
to be highest in the group with the highest BODE scores 105.93 (std. deviation 
53.48). it was not significantly different between the control(2.60) and the mild 
COPD (7.13) groups and in the moderate group the titer was 33.72. The difference 
was statistically significant with a P value of 0.05. 
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Fig 5: Duration of hospital stay 
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Fig 7: QRS AXIS IN ECG 
 
 
55 
 
 
 
 
 
56 
 
 
 
 
 
 
57 
 
DISCUSSION 
                      COPD is predicted to be one among the most common killer diseases 
affecting a large number of individuals by the year 2020. In the recent past, more 
stress has been given to formulate a simple but effective index for assessing the 
severity of COPD. Researchers have found that BODE index would fulfill this 
necessity. But most of the research has been limited to finding the usefulness of the 
index in predicting the mortality and hospitalization in patients with COPD. In our 
study we tried to evaluate its usefulness in predicating the severity of COPD in 
terms of hospitalization, systemic involvement and the level of systemic 
inflammation. Our research has brought out many results which would have a 
significant impact in the management of COPD in the future. 
                     We included only male patients in our research, since COPD is more 
common among male patients. This was aimed at making the study group as 
uniform as possible. Such a selection would negate the differences in the BODE 
index among various patients studied, by removing the gender related differences 
in FEV1, BMI and patient perception of dyspnea. 
                    Studies by Celli etal5 and Kian-Chung etal2 has proven that grouping 
COPD patients into three groups with BODE scores 0 – 2 as first group, 3 – 5 as 
second and 6 or more as the third group correlates well with severity in terms of 
58 
 
hospitalization and mortality. Hence we have accepted the same classification and 
grouped the above groups as mild, moderate and severe COPD. Our study 
individuals were almost equally distributed in the various groups. 30 controls were 
also selected. 
                      Kian-chung etal2 and Celli etal5 has shown in their respective studies 
that BODE score increases with age. This study also shows a significant increase 
in the severe and moderately severe group compared to controls. This could be due 
to the progression of COPD with age. However results from a few other studies 76, 
77 do not significant progression with age. This difference is mainly due to the fact 
that duration of smoking was not proportional to age in those groups unlike in our 
study. 
                   Results from this study go along with most other studies, in the 
relationship of smoking to BODE index. Studies by Kian-chung etal2, Celli etal5, 
and Karoli etal85 have all proven beyond doubt that higher duration of smoking is 
associated with higher BODE index. The study revealed that there was significant 
increase in the BODE index in patients with a higher duration of smoking. The 
difference was not statistically significant among the control group and those in the 
mild COPD group. This probably means that the disease could still be reversed 
with the cessation of smoking. 
59 
 
                    A multiple component staging system combining FEV1, 6-min walking 
distance, dyspnea scored with the MMRC scale, and PaO2 was reported to better 
describe health-care resources utilization among COPD patients in different 
geographic areas when compared to international COPD classifications (ATS, 
British Thoracic Society, and GOLD)86. The BODE index was also reported to be a 
much better predictor of the severity in COPD acute exacerbations than FEV12. Our 
findings of the usefulness of the BODE index in predicting hospitalization for 
COPD are also supported by the findings of a prospective study29 of risk factors of 
hospital readmissions for COPD exacerbation. In that study, a strong association 
between the usual physical activity and reduced risk of COPD readmission was 
demonstrated. Moreover, the association did not change when adjusted for FEV1 or 
nutritional status. These results are in agreement with the increased risk of COPD 
hospital admission associated with a limited 6-min walking test reported by another 
group of investigators23. Therefore, it may be speculated that the superior value of 
the BODE index compared to FEV1 in predicting hospital admissions for COPD 
that we have observed, is accounted for by the evaluation of physical performance 
status among the individual components of the BODE scoring system.  
                       Admission to the hospital and heavy use of health-care resources is a 
common feature of COPD. A clinical implication of the present study is that the 
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BODE scoring system may prove to be helpful in health-care resource allocation 
and in guiding therapy for individual patients in the future. This multistage scoring 
system, which incorporates variables that can be evaluated easily in any office 
setting, should not be difficult or costly to implement routinely. As the BODE 
index can provide useful prognostic information of survival and hospitalization, the 
findings of the present study are in support of the utility of the BODE index as an 
assessment tool for COPD patients. 
                     To our knowledge, this is the first study to show that the BODE 
staging system predicts the severity of systemic involvement in patients with 
COPD. The parameters that we assessed to this regard were the body mass index, 
hemoglobin and albumin concentration, ECG axis, ejection fraction and pulmonary 
hypertension in ECHO and systemic inflammation as assessed by the CRP value.  
                    While considering BMI as a criteria for BODE index scoring, 
significance is only given to whether it is more, or less than 21. In our study we 
found that the BMI progressively declines with severity among the patients with 
COPD. Emil etal4 had described the depletion of free fat mass and thereby a 
reduction in BMI in patients with COPD. Our finding is further supported by 
various studies69, 70 that evaluated the systemic effects of COPD. An imbalance in 
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the continuously ongoing process of protein degradation and replacement can be 
hypothesized as a mechanism contributing to this wasting condition. 
                    Polycythemia has frequently been reported in patients with COPD, 
owing to the increased erythropoietin production induced by chronic hypoxia. 
However in our study we found that in the group with mild disease according to 
BODE scores, the mean hemoglobin concentration was lower than the control 
group. But as severity increases the mean hemoglobin concentration was found to 
increase. Though the initial decrease was statistically insignificant, it could be 
attributed to the nutritional deficiencies that occur due to the disease state. More 
studies are required to prove this. 
                   Burch et al65 and Caird et al69 have shown that most of the cases (80%) 
of severe COPD are associated with right axis deviation. We could replicate this in 
our study population. In our study 61.7 % of individuals had normal axis, 28.3 % 
had right axis deviation, 7.5 % LAD and 2.5 % had northwest axis.  However in 
the severe COPD group 86.3 % individuals had right axis and 10.3 % Northwest 
axis which was significantly higher compared to other groups. This could be 
attributed to the higher level of deterioration in lung function and pulmonary 
hypertension in these individuals.  
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                   The echocardiography findings in our study were generally in 
agreement with other studies conducted. However studies have detected only mild 
reduction in ejection fraction among patients with COPD. In our study the 
reduction in ejection fraction was very significant especially in the group with 
severe COPD. This could probably be because of higher incidence of other causes 
of dilated cardiomyopathy in our group like ischemia, as smoking is a common 
risk factor. The LV dysfunction in COPD is believed to be due to Bernheim’s 
effect due to paradoxical movement of the interventricular septum in patients with 
COPD. 
                  Arcasoy et al87 has demonstrated an incidence of pulmonary 
hypertension of around 16 % in patients with COPD. Stevens et al88 showed that 
the proportion of patients with pulmonary hypertension is higher among patients 
with severe COPD. Our study revealed a total incidence of 32.5 % of PAH among 
patients with COPD. The proportion was higher in the severe group with 58.6 % 
having moderate PAH and 24.1 % having severe PAH. The pulmonary 
hypertension in patients with COPD occurs due to a variety of factors including 
pulmonary vasoconstriction due to alveolar hypoxia, acidemia and hypercarbia; 
compression of pulmonary vessels due to increased lung volume; loss of small 
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vessels due to lung destruction, and increased blood viscosity and cardiac output 
due to polycythemia secondary to hypoxia. 
                     Li et al80 have reported direct effects of TNF α and demonstrated 
time-dependent and concentration-dependent reductions in total protein content in 
patients with COPD. Wouters et al81 also demonstrated hypoalbuminemia in 
patients with COPD. In our study we found significant reduction in serum albumin 
concentrations with increase in severity of COPD as assessed by the BODE score. 
                    Among the markers of systemic inflammation, we concentrated on C 
reactive protein since it has been shown to upregulate the production of 
proinflammatory cytokines and tissue factors by monocytes, increase the uptake of 
LDL by macrophages and directly induce expression of adhesion molecules by the 
human endothelial cells. Additionally CRP may deposit directly into the arterial 
wall during atherogenesis, interacting with other inflammatory mediators to create 
foam cells, which serve as building blocks to atherosclerotic plaques. Cirillo et al 90 
showed an increasing CRP value with worsening airflow obstruction. Our study 
has shown that moderate and severe, but not mild COPD is associated with 
significant levels of low grade systemic inflammation. Study done by Sin et al89, 
also revealed similar findings.   
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LIMITATIONS OF THE STUDY 
1. We would like to acknowledge that a relatively small number of patients 
were evaluated and that the number of patients required to detect a 
significant difference in the predictive power of the BODE index and FEV1 
were not been prospectively determined. 
2. The study is a hospital based study and may not be representative of the 
general population. 
3. Caution is required while using the results in populations outside India 
because there have been no systematic comparisons of the regional 
manifestations of COPD. 
4. Only males were inducted into the study. Hence the results of the study 
cannot be used in female patients with COPD. 
5. As a cross sectional study, the present analysis is limited in its ability to 
elucidate, whether improving the BODE index reverses the various 
parameters analyzed. 
6. Alternate causes and medication effects influencing the parameters analyzed 
should also be considered. 
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CONCLUSIONS AND SUMMARY 
 
1. BODE index can be used as a reliable index to assess the severity of 
chronic obstructive pulmonary disease. 
2. BODE index is directly correlated with the duration and intensity of 
smoking. 
3. BODE index predicts hospitalization due to causes related to COPD. 
4. Polycythemia is associated with more severe disease. 
5. Cardiac effects of the disease increases with the severity of disease as 
assessed by BODE index. 
6. BODE index directly correlates with nutritional derangement in 
patients with COPD as evidenced by the changes in BMI and serum 
albumin. 
7. Intensity of systemic inflammation increases with increase in the 
severity of disease. 
           Thus our study concludes that BODE index is reliable method to 
predict hopitalisation and the severity of systemic involvement in patients 
with COPD. Since the assessment of BODE index requires only a 
spirometer, which is relatively inexpensive and can easily be made available, 
this index could be of great practical value in a primary health care setup to 
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identify individuals who are at need for further evaluation in a higher center. 
Thus the BODE index can be used for judicious referral of patients with 
COPD thereby preventing the wastage of the limited resources available.   
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SCOPE FOR FUTURE STUDIES 
                 The study conducted in our population has many significant 
observations and potential implications. Our study concludes that BODE index is 
reliable method to predict hospitalization and the severity of systemic involvement 
in patients with COPD. Future studies are needed to assess whether it can be used 
as a reliable index to monitor the progress of disease. Studies are also needed to 
assess whether reduction in BODE index improves the disease status. The 
incidental finding whether hemoglobin concentration decreases initially in patients 
with COPD could also be subjected to further research. 
                Future research should also aim at finding the intervention measures 
which have the greatest impact on BODE index and thereby the severity of the 
disease. We do not know whether it will be a useful indicator of the outcome in 
clinical trials, the degree of utilization of health care resources, or the clinical 
response to therapy. More studies are needed in this regard. 
              To summarize, the BODE scoring system is reliable index to predict 
hospitalizations and the severity of systemic involvement in patients with COPD. 
Besides its excellent predictive power with regard to outcome, the BODE index is 
simple to calculate and requires no special equipment. This makes it a practical tool 
of potentially widespread applicability. 
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PROFORMA 
 
Name:                                      age:                      sex:                        serial no:  
Occupation:                                                          address: 
 
Symptoms: 
 
Smoker                      :            Y/N 
Cough                       :            Y/N 
Sputum                     –            nil /  scanty / moderate / copious 
Breathlessness          –            nil / exertional / orthopnea / PND  
MMRC scale            :             0 1 2 3 4 
Seasonal variation    :            Y/N 
Nocturnal symptoms:            Y/N 
 
Exclusion history: 
 
H/o Unrelated life threatening major illness (If yes specify): 
H/o Spirometry proved bronchial asthma          : 
H/o Myocardial infarction in the past 4 months: Y/N 
H/o unstable angina                                           : Y/N 
H/o congestive heart failure                              : Y/N 
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H/o inability to walk                                         : Y/N 
 
End points: 
 
Number of hospital admission in the past 2 yrs due to causes directly related to 
COPD: 
 
Examination:  
Body wt Æ                                        Height Æ 
BMI {Wt (kg)/ [Ht(ms)]^2 }Æ  
Cyanosis:                                       clubbing:                                      edema: 
JVP: 
PR:                                                   BP:                                                RR: 
 
Respiratory system: 
AP diameter :                                        Transverse diameter: 
Rhonchi        :          Y/N                       Crepitations            : Y/N 
 
Other systems: 
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Investigations:  
Hb –                             TC                 DC 
 
ECG Æ   QRS AXIS –                 P pulmonale Æ             
 
Echo Æ    EF –                     PAH –                            RV diameter –  
 
6 min walk test Æ         >350 ms  /  250 – 349  /   150 – 249  /   <149 
 
FEV1 Æ                          >/= 65   /     50 – 64    /     36 – 49    / < /= 35 
FEV1/FVC Î 
Post bronchodialator FEV1Æ 
 
CRPÆ 
 
LFT        total prot :              albumin :  
Estimated BODE score                             Æ    score 
• FEV1                                                 Æ  
• Distance walked in 6 mins                Æ 
• MMRC dyspnea scale                       Æ 
• BMI                                                   Æ 
                                                                          ------------ 
*           Total BODE score Æ 
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MMRC dyspnea scale   
 
Grade 0 – no dyspnea / only on severe exertion 
Grade 1 – dyspnea on hurrying / walking up a hill 
Grade 2 – walks slower than normal at level/ pause while walking on level ground 
Grade 3 – stops for breath after walking 100 yards/few mins on level ground 
Grade 4 – too breathless to leave the house/ dyspnea on dressing 
 
BODE INDEX: 
 
BODE score 0  1 2 3 
FEV1 >/= 65 %  50 – 64% 36 – 49% < /= 35% 
6 min walk 
test 
>350 ms   250 – 349ms 150 – 249 ms <149 ms 
Dyspnea 
scale 
0 – 1  2 3 4 
BMI > 21 kg/m2 <21 kg/m2   
 
Mild COPD Æ 0 – 2  
Moderate COPD Æ 3 – 5 
Severe COPD Æ >/= 6 
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ABBREVIATIONS 
 
COPD  Æ Chronic obstructive pulmonary disease 
FEV1   Æ forced expiratory volume in one second 
BODE  Æ body-mass index (B), airflow obstruction (O), dyspnea(D), and exercise 
                 capacity (E) 
GOLD Æ Global initiative for obstructive lung diseases 
ATS    Æ American Thoracic Society 
ERS    Æ European Respiratory Society 
RV      Æ Residual Volume 
FRC    Æ Forced Respiratory Capacity 
TV      Æ Tidal Volume 
α 1 ATÆ Alpha 1 antitrypsin 
HNE   Æ Neutrophil elastase  
BCM  Æ Body cell mass 
FFM   Æ Fat free mass 
BMI   Æ Body mass index 
IFN    Æ Interferon  
CRP  Æ C reactive Protein 
 
 
